SCG3 and retinopathy of prematurity: Our findings also demonstrated that Scg3-neutralizing monoclonal antibodies (mAbs) mitigated pathological RNV in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, with minimal adverse effects on the developing retina and other organ systems [6,13].